Antiphospholipid Syndrome Clinical Trial
Official title:
Detection Of Anti-Double Stranded Deoxyribonucleic Acid Antibodies In Autoimmune Rheumatic Diseases: Comparison Between Immunofluorescence And Enzyme Immunoassay
detection of anti-ds DNA in patients with rheumatic diseases by two methodes : immunofluorescence & ELISA
Autoimmune rheumatic diseases are autoimmune disorders presented with joint and muscles
manifestations. However, other organs may be involved at a varying degree in different
conditions. They are also called connective tissue diseases (CTDs) or collagen diseases. They
include systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), Sjiogren's syndrome
(SjS), systemic sclerosis, polymyositis and dermatomyositis and mixed connective tissue
disease (Peakman and Vergani, 2009).
Autoimmune rheumatic diseases are characterized by presence of antinuclear antibodies (ANA).
These antibodies are involved in the disease pathogenesis, and their presence in patients'
sera constitutes one of the criteria used (together with the clinical manifestations) for
disease diagnosis (Stevens, 2010). ANA include autoantibodies to extractable nuclear antigens
and autoantibodies to histones and deoxyribonucleic acid (DNA).
Anti-DNA antibodies include those against single and double stranded DNA (ssDNA and dsDNA,
respectively). Anti-dsDNA antibodies are recognized as diagnostic markers of SLE and as
indicators of SLE disease activity, especially in lupus nephritis (Zigon et al.,
2011).However, high anti-dsDNA levels are found only in 50-70% of SLE patients. So, negative
anti-dsDNA test does not exclude SLE Also, anti-dsDNA antibodies can be detected in other
autoimmune diseases such as RA and SjS, as well as in healthy blood donors (Zigon et al.,
2011).The significance of anti-dsDNA in SLE diagnosis and in monitoring SLE disease activity
has led to an increase in this test laboratory requests as well as in the number of
commercially available kits (Chiaro et al., 2011).
The kits that are used in detection and quantitation of anti-dsDNA antibodies include:
1. Radioimmunoassay methods developed according to Farr technique (FARR-RIA) (Wold et al.,
1968). However, due to the use of radioactive element in the Farr assay, it is not
widely used in the routine diagnostic laboratory work (Mahler and Fritzler, 2007).
2. Crithidia luciliae immunofluorescence test (CLIFT) developed by Aarden et al (1975)
detects anti-dsDNA by indirect immunofluorescence using the hemoflagellate Crithidia
luciliae which contains kinetoplast that contains a high concentration of native (dsDNA)
DNA (Zigon et al., 2011). However, reading and interpretation of the immunoflourescence
is subjective and depends on the experience and training of the laboratory personnel
which could affects the test results (Chiaro et al., 2011).
3. Enzyme-linked immunosorbant assay (ELISA) is simple to perform, does not require highly
trained operators and can be automated. Therefore, it is becoming the most widely used
method (Kumar et al., 2009).With the increasing number of anti-dsDNA ELISA assays, the
potential for variability in the diagnostic accuracies is enormous as different
antigens, assay principles and cutoff determinations are employed (Chiaro et al., 2011).
Anti- dsDNA ELISAs may give false-positive results due to binding of immune complexes to
the pre-coat intermediates (Zigon et al., 2011).
In the Laboratory of Clinical Immunology, Assiut University Hospital, we shifted from manual
ELISA kits to automated ELISA platform (Alegria system, Orgentec Diagnostika, Germany) and
recently CLIFT was introduced in the laboratory.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01475149 -
Effect of HCQ on AnxA5 Resistance Assay in Antiphospholipid (aPL) Positive Patients With and Without Systemic Lupus Erythematosus (SLE)
|
N/A | |
Completed |
NCT00537290 -
A Pilot Study of Rituximab for the Anticoagulation Resistant Manifestations of Antiphospholipid Syndrome
|
Phase 2 | |
Recruiting |
NCT00616317 -
Register for Pediatric Patients With Antiphospholipid Syndrome (APS): European Project Extended Internationally Study
|
||
Recruiting |
NCT00198068 -
Predictors of Pregnancy Outcome in Systemic Lupus Erythematosus (SLE) and Antiphospholipid Syndrome (APS)
|
||
Completed |
NCT00180817 -
Longitudinal Study of the Clinical and Haematological Cause of Women With Antiphospholipid Antibodies.
|
||
Completed |
NCT03682419 -
Evaluation of Precision and Accuracy of INR Measurements in a Point of Care Device (OPTIMAL)
|
N/A | |
Recruiting |
NCT04262492 -
International Registry of Thrombotic APS Patients Treated With Direct Oral Anticoagulants
|
||
Withdrawn |
NCT00180778 -
Steroids and Antiphospholipid Syndrome- Related Pregnancy Loss
|
Phase 1/Phase 2 | |
Enrolling by invitation |
NCT05583305 -
Prevalence and Etiologies of Intracranial Stenosis in Patients With Antiphospholipid Syndrome
|
||
Recruiting |
NCT05644210 -
Telitacicept Followed With Rituximab Therapy on APS Secondary to SLE
|
||
Recruiting |
NCT02303171 -
Use of Warfarin After the First Trimester in Pregnant Women With APS
|
Phase 4 | |
Not yet recruiting |
NCT06420154 -
The Safety and Efficacy of Anti-CD19 CAR-T Cells in Patients With Relapsed/Refractory Autoimmune Diseases
|
Early Phase 1 | |
Completed |
NCT00674297 -
Effects of Fluvastatin on Proinflammatory and Prothrombotic Markers in Antiphospholipid Syndrome Patients
|
Phase 2 | |
Recruiting |
NCT05859997 -
Universal CAR-T Cells (BRL-301) in Relapse or Refractory Autoimmune Diseases
|
N/A | |
Recruiting |
NCT06373003 -
Negative Antiphospholipid Syndrome: a Multicentric Study
|
||
Recruiting |
NCT06373926 -
Evaluation of Cell Membrane Expression of Annexin A2 on Monocytes by Flow Cytometry in Primary Antiphospholipid Syndrome
|
N/A | |
Recruiting |
NCT01818505 -
The Influence of Antiphospholipid Antibodies on the Relationship Between Hyperurecemia, Gout and Metabolic Syndrome
|
N/A | |
Completed |
NCT00878137 -
Reliability of Point-of-care INR Measurements in Patients With Antiphospholipid-antibody Syndrome Treated With Warfarin
|
N/A | |
Completed |
NCT01104337 -
Drug Interaction Between Paracetamol and Warfarin
|
Phase 4 | |
Completed |
NCT05313048 -
Prospective Observational Study to Evaluate a Possible Change in APS Antibody Profiles After COVID-19 Infection or Vaccination
|